Trials / Completed
CompletedNCT01805544
Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication
Satisfaction and Quality of Life in Patients With a Diagnosis of DVT (Deep Venous Thrombosis) Who Take Rivaroxaban
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 113 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
National, multicenter, prospective, observational, non-interventional study. The objective is to determine if the switch from Vitamin K antagonists (VKA) to Xarelto in subjects treated with VKA with issues in deep venous thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) is associated with an improvement of the treatment satisfaction after 3 months. The treatment satisfaction will be measured by the Anti Clot Treatment Scale (ACTS) score.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivaroxaban (Xarelto, BAY59-7939) | 20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2015-04-01
- Completion
- 2015-06-01
- First posted
- 2013-03-06
- Last updated
- 2017-01-23
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01805544. Inclusion in this directory is not an endorsement.